Showing 15 posts of 242 posts found.

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

August 29, 2023
Sales and Marketing Elahere, Immunogen, Oncology, Takeda

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …

FDA grants Priority Review for Takeda’s cTTP treatment

May 17, 2023
Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …


Takeda collaboration to optimise biopharmaceutical manufacturing announced

June 22, 2021
Manufacturing and Production Takeda, collaboration, manufacturing

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering (RCPE), InSilicoTrials, and the University …

Takeda building

Takeda’s lung cancer drug granted FDA priority review

April 29, 2021
FDA, Takeda, lung cancer treatment, pharma, pharma news

The FDA has granted priority review for Takeda’s New Drug Application (NDA) for its mobocertinib drug for the treatment of …

Takeda building

Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio

March 10, 2021
Research and Development Maverick, Takeda, cancer treatment

Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of …

Takeda building

Takeda agree $856m deal with Ovid to take over soticlestat development

March 4, 2021
Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat

Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …


Takeda sells four diabetes products to Teijin Pharma for $1.25m

February 26, 2021
Medical Communications Takeda

Takeda has entered into an agreement to transfer the assets, marketing rights, and, eventually, marketing authorisation associated with a portfolio …


Takeda’s breast cancer treatment approved in Scotland

February 9, 2021
Manufacturing and Production Takeda, breast cancer

The Scottish Medicines Consortium has accepted Takeda’s PROSTAP 3 DCS (leuprorelin acetate) treatment for use in patients with early and …

NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

December 10, 2020
Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda

NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …


China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12

December 8, 2020
Manufacturing and Production, Sales and Marketing China, Takeda

China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …

Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy

November 30, 2020
Sales and Marketing Cabometyx, Japan, Takeda

The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …


Takeda commits to deliver 50 million doses of Moderna’s COVID-19 vaccine in Japan

October 29, 2020
Manufacturing and Production, Sales and Marketing COVID-19, Japan, Moderna, Takeda, Vaccine

Takeda has made a commitment with Japan’s Ministry of Health, Labor and Welfare (MHLW) to deliver 50 million doses of …


Takeda and Arrowhead Pharma join forces in $1m rare liver disease drug development pact

October 9, 2020
Medical Communications, Research and Development Arrowhead, Takeda, pharma

A new partnership has been struck between Takeda and Arrowhead Pharmaceuticals, with both companies coming together to co-develop and license …


Takeda to sell another non-core portfolio for $260 million to Cheplapharm

September 8, 2020
Manufacturing and Production, Sales and Marketing Cheplapharm, Takeda, pharma

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an …

Latest content